AKTS – Akoustis Technologies Inc
AKTS — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
4.15
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.04
EPS Last/This Y
1.44
EPS This/Next Y
0.25
Price
0.04
Target Price
32.5
Analyst Recom
1
Performance Q
Upside
N/A
Beta
Ticker: AKTS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | AKTS | 19.1 | N/A | N/A | 0 |
| 2026-03-10 | AKTS | 19.01 | N/A | N/A | 0 |
| 2026-03-11 | AKTS | 19.29 | N/A | N/A | 0 |
| 2026-03-12 | AKTS | 18.3 | N/A | N/A | 0 |
| 2026-03-13 | AKTS | 18.29 | N/A | N/A | 0 |
| 2026-03-17 | AKTS | 19.31 | N/A | N/A | 0 |
| 2026-03-18 | AKTS | 18.28 | N/A | N/A | 0 |
| 2026-03-20 | AKTS | 17.65 | N/A | N/A | 0 |
| 2026-03-25 | AKTS | 18.64 | N/A | N/A | 0 |
| 2026-03-26 | AKTS | 17.68 | N/A | N/A | 0 |
| 2026-03-27 | AKTS | 15.21 | N/A | N/A | 0 |
| 2026-03-30 | AKTS | 16.55 | N/A | N/A | 0 |
| 2026-03-31 | AKTS | 17.92 | N/A | N/A | 0 |
| 2026-04-01 | AKTS | 17.12 | N/A | N/A | 0 |
| 2026-04-06 | AKTS | 16.38 | N/A | N/A | 0 |
| 2026-04-07 | AKTS | 16.74 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | AKTS | 34.17 | 5.61 | 3.33 |
| 2026-03-10 | AKTS | 34.17 | 5.61 | 3.33 |
| 2026-03-11 | AKTS | 34.17 | 5.61 | 3.63 |
| 2026-03-12 | AKTS | 34.17 | 5.61 | 3.63 |
| 2026-03-13 | AKTS | 32.00 | 5.61 | 3.45 |
| 2026-03-18 | AKTS | 32.00 | 5.62 | 3.45 |
| 2026-03-19 | AKTS | 32.00 | 5.62 | 3.45 |
| 2026-03-20 | AKTS | 32.00 | 5.62 | 3.45 |
| 2026-03-23 | AKTS | 32.00 | 5.62 | 3.45 |
| 2026-03-24 | AKTS | 32.00 | 5.62 | 3.45 |
| 2026-03-25 | AKTS | 32.00 | 5.62 | 4.02 |
| 2026-03-26 | AKTS | 32.00 | 5.62 | 4.02 |
| 2026-03-27 | AKTS | 32.00 | 5.62 | 4.02 |
| 2026-03-30 | AKTS | 32.00 | 6.86 | 4.02 |
| 2026-03-31 | AKTS | 32.00 | 6.86 | 4.02 |
| 2026-04-01 | AKTS | 32.00 | 6.86 | 4.02 |
| 2026-04-02 | AKTS | 32.00 | 6.86 | 4.02 |
| 2026-04-06 | AKTS | 33.42 | 9.84 | 4.15 |
| 2026-04-07 | AKTS | 33.42 | 9.84 | 4.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
33.42
Institutional Transactions
9.84
Beta
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
54
Growth Score
48
Sentiment Score
13
Actual DrawDown %
99.8
Max Drawdown 5-Year %
-99.8
Target Price
32.5
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
-0.45
EPS Next Y. (Est.)
-0.2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.83
Return on Equity vs Sector %
183.5
Return on Equity vs Industry %
216.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.09
EBIT Estimation
◆
AKTS
Healthcare
$16.72
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42.7
Range 1M
31%
Sup Dist
5.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
24.1%
EPS NY
-30.3%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+94.4% upside
Upside
+94.4%
Aktis Oncology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 79
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
AKTS
Latest News
—
Caricamento notizie per AKTS…
stock quote shares AKTS – Akoustis Technologies Inc Stock Price stock today
news today AKTS – Akoustis Technologies Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AKTS – Akoustis Technologies Inc yahoo finance google finance
stock history AKTS – Akoustis Technologies Inc invest stock market
stock prices AKTS premarket after hours
ticker AKTS fair value insiders trading